Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AVACTA GROUP PLC Regulatory Filings 2015

Sep 10, 2015

7507_rns_2015-09-10_ed3c64e9-456b-49b2-883a-6a9c5bc9ec19.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6126Y

Avacta Group PLC

10 September 2015

10 September 2015

Avacta Group plc

("Avacta", the "Company" or the "Group")

Total Voting Rights

The Company would like to confirm that Avacta's issued share capital consists of 6,740,649,550 Ordinary Shares of 0.1p each with voting rights, and not 6,740,149,550 as was incorrectly stated in the Company's announcement on 3 September 2015.

The above figure of 6,740,649,550 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules. The Company does not hold any shares in Treasury.

- Ends -

For further information:

Avacta Group plc

Tim Sykes, Chief Financial Officer
Tel:  +44 (0) 844 414 0452

www.avacta.com
Numis Securities Limited    

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking
Tel:  +44 (0) 207 260 1000

www.numiscorp.com
Media Enquiries

FTI Consulting

Simon Conway/Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000

[email protected]

About Avacta Group plc - www.avacta.com

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through two divisions:

Avacta Animal Health

www.avactaanimalhealth.com
Veterinary diagnostics reference laboratory and diagnostic kit provider.
Avacta Life Sciences

www.avactalifesciences.com
Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRLKLLBEKFLBBV